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Although recombinant human bone 
morphogenetic proteins (BMPs) are used 
locally for treating bone defects in men, their 
systemic effect on bone augmentation has not 
been explored. We have previously 
demonstrated that demineralized bone (DB) 
from ovariectomized (OVX) rats can not induce 
bone formation when implanted ectopically at 
the subcutaneous site. Here we showed in vitro 
that 17β-estradiol (E2) specifically induced 
expression of BMP-6 mRNA in MC3T3-E1 
preosteoblastic cells and that bone extracts 
from OVX rats lack BMPs. Next we 
demonstrated that 125I-BMP-6 administrated 
systemically accumulated in the skeleton and 
also restored the osteoinductive capacity of 
ectopically implanted DB from OVX rats. 
BMP-6 applied systemically to aged OVX rats 
significantly increased the bone volume and 
mechanical characteristics of both the 
trabecular and cortical bone, the osteoblast 
surface, serum osteocalcin and osteoprotegerin 
levels, and decreased the osteoclast surface, 
serum C-telopeptide and IL-6. E2 was 
significantly less effective, and was not 
synergistic with BMP-6. Animals that 
discontinued the BMP-6 therapy maintained 
the bone mineral density gains for another 12 
weeks. BMP-6 increased in vivo the bone 
expression of ALK-2, ALK-6, Smad 5, alkaline 
phosphatase, collagen type I and decreased the 
expression of BMP-3 and BMP antagonists, 
chordin and cerberus. These results show, for 
the first time, that systemically administered 
BMP-6 restores the bone inductive capacity, 
microarchitecture and quality of the skeleton in 
osteoporotic rats.  
 
 
 
Bone loss during aging and after 
menopause in women is known to result from an 
imbalance between bone formation and resorption 
leading to altered bone microarchitecture and 
excess bone fragility. Inferior bone strength and 
increased bone fracture rate of bone in patients 
with osteoporosis might be associated with 
decreased osteoinductive and thus self-
regenerative bone capacity eventually due to lower 
content of growth and differentiation factors 
including bone morphogenetic proteins in the bone 
extracellular matrix (1-4).  
Demineralized bone matrix (DBM) 
induces de novo bone formation when implanted 
into the rat muscle (5). On the contrary, DBM 
from OVX animals implanted into both normal 
and OVX rats induces only fibrous tissues 
suggesting that its decreased bone inducing 
activity is due to abnormal composition of bone 
from OVX rats and not to the 17β-estradiol (E2) 
deficient microenvironment (1). Lack of specific 
signals needed for ectopic bone induction may, at 
least in part, explain diminished bone potency to 
heal fractures in osteoporotic patients (6,7). It has 
been demonstrated that fetal osteoblastic cell lines 
treated by E2, specifically express BMP-6 mRNA, 
while gene transcripts of other members of the 
BMP family are unaffected (8). A functional 
relationship between E2 and BMP-6 was further 
suggested by E2 binding to BMP-6 gene promotor 
(9) and by increased BMP-6 immunostaining in 
bone marrow of mice treated with E2 (10).  
Although numerous studies have 
unequivocally demonstrated that BMPs induce 
new bone formation locally in animals and men, 
both ectopically and when implanted between 
bone ends in patients with delayed non-unions or 
acute fractures (11,12), so far it has not been 
shown that a systemically administered 
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recombinant BMP can effect the bone volume in 
OVX rats.  
In these studies we tested the effect of 
systemically administered recombinant BMP-6 on 
the bone formation in aged OVX rats and showed 
for the first time that BMP-6 is a novel systemic 
bone anabolic agent and has a potential for treating 
bone loss in patients with osteoporosis.   
 
Experimental Procedures 
 
Demineralized bone matrix (DBM) - Bone matrix 
was prepared from 6 months old Sprague-Dawley 
rats, 3 months following OVX.  After sacrifice, 
diaphyses of femurs and tibiae were removed and 
then powdered, sieved and demineralized as 
previously described (5). DBM from OVX rats 
was implanted subcutaneously (sc) in the pectoral 
region of normal and OVX rats, which were 
subsequently injected with 20, 50 and 100 
μg/kg/day of BMP-6 intravenously (iv) from days 
2 to 6 following implantation. Two weeks 
following implantation DBM, pellets were 
removed and embedded in paraffin, cut, stained 
with toluidin blue and examined for the presence 
of new cartilage and bone.   
MC3T3-E1 preosteoblastic cell line and cell 
culture experiments - Stock cultures of non-
confluent mouse-calvarial preosteoblasts (MC3T3-
E1) were grown in alpha minimal essential 
medium (α-MEM), supplemented with 10% fetal 
calf serum and 1% penicillin/streptomycin at 
37 °C in a humidified atmosphere of 95% air and 
5% CO2. All culture reagents were from Life 
Technologies (Rockville, MD). MC3T3-E1 cells 
were obtained from American Type Culture 
Collection (Manassas, VA). Cells were plated at 
3×104 cells/cm2 in 24-multiwell culture dishes 
(Costar) and cultured until reaching approximately 
90% confluence. The growth medium was 
replaced by DMEM-F12 (without phenol red; Life 
Technologies) supplemented with ITS+culture 
supplement (Collaborative Biomedical Products, 
Bedford, MA) and -ascorbic acid 2-sulfate (50 
μg/ml; Sigma, St Louis, MO). Cells were 
stimulated with E2, (Sigma, St. Louis, MO) at 
10−7–10−11 M for 12 and 72 h. At designated time 
points total cellular RNA was extracted and 
analyzed by semi-quantitative PCR. 
Animals - Four, 6 or 7 months old Sprague-
Dawley rats were subjected to OVX. Animals 
were anesthetized with an intraperitoneal injection 
of thiopenthal at doses of 4 mg/kg body weight. 
Thirty animals per experiment were subjected to 
sham surgery during which the ovaries were 
exteriorized but replaced intact. Bilateral 
ovariectomies were performed in the remaining 
rats from the dorsal approach and they were left 
untreated for a period of 6 to 18 months following 
surgery to await the development of osteopenia. 
BMP-6 at doses of 1, 10, 25 and 50 µg/kg was 
injected through the rat tail vein one or three times 
a week for 8 to 12, or 30 weeks (extended 
protocol). In total 390 sham and OVX rats were 
used in three protocols as follows:  
a. (1) sham (n=30), (2) OVX (n=20), (3) 
OVX + BMP-6 (10 μg/kg intravenously (iv) 
3xweek) (n=20), (4) OVX + BMP-6 (25 μg/kg iv 
3xweek) (n=20), (5) OVX + BMP-6 (50 μg/kg iv 
3xweek) (n=20), (6) OVX + E2 (50 μg/kg 
intraperitoneally, ip 3xweek) (n=20) and (7) OVX 
+ E2 (50 μg/kg ip 3xweek) + BMP-6 (50 μg/kg iv 
3xweek) (n=20). Therapy started 12 months 
following OVX and continued for 12 weeks 
(Figure 2). 
b. (1) sham (n=30), (2) OVX (n=20), (3) 
OVX + BMP-6 (10 μg/kg iv 3xweek) (n=50) for 3 
months and then group (3) OVX + BMP-6 was 
divided into: (4) OVX + BMP-6 (10 μg/kg iv 
3xweek) (n=20), (5) OVX + E2 (50 μg/kg ip 
3xweek) (n=20) and (6) OVX + no therapy (n=10) 
for 4.5 months. Therapy started 6 months 
following OVX and continued for 7.5 months 
including first therapy (3 months) and second 
therapy (3.5 months), (Figure 4). 
c. (1) sham (n=30), (2) OVX (n=20), (3) 
OVX + BMP-6 (1 μg/kg iv 3xweek) (n=20), (4) 
OVX + BMP-6 (10 μg/kg iv 3xweek) (n=20) and 
(5) OVX + BMP-6 (10 μg/kg iv 1xweek) (n=20). 
Therapy started 18 months following OVX and 
continued for 6 weeks (Figure 5). 
All experiments and protocols were approved by 
the Institutional Animal Care Committee and the 
Ministry of Science and Technology (project 
108295). 
Recombinant BMP-6 - Human mature BMP-6 was 
produced in CHO cells as previously described 
(13, 14). Proteins were purified by using a Filtron 
Minisette (PallGelman) cross flow device. pH was 
adjusted to 5.5 and the material was dialyzed 
against 0.1 M Tris, 75 mM acetic acid, 0.2 M 
KH2PO4, 5 mM EDTA, 6 M urea and then 
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filtered. Subsequently, ca. 150 mg protein was 
loaded onto a 5 ml HiTrapTM Heparin Sepharose 
HP (Amersham Biosciences) column that had been 
preequilibrated with 0.1 M Tris, 125 mM acetic 
acid, 5 mM EDTA and 6 M urea containing 0.3 M 
NaCl. Loading was performed at a flow rate of 4 
ml/min. The column was loaded with maximal 30 
mg of dialyzed protein. Dimeric BMP-6 species 
was eluted at a NaCl concentration of 0.7 M. 
Homogenous fractions were pooled, dialyzed 
against 10 mM NH4-acetate, pH 4.0, lyophilized, 
and stored until used. 
Biodistribution and pharmacokinetics of 125I-
labeled BMP-6 (125I-BMP-6) - Highly purified 
BMP-6 (15.7 mg) was radioiodinated with 5 mCi 
of carrier-free Na 125I using a modification of the 
lactoperoxidase method as described earlier (15, 
16). Shortly, gel filtration on a Sephadex G-25 
column was used to separate radioiodinated BMP-
6 (125I-BMP-6) from the free iodide. The column 
was eluted with 20 mM sodium acetate buffer, pH 
4.5 containing 0.2 Tween-80 and 0.1% ovalbumin. 
The specific activity of the 125I-BMP-6 preparation 
used in this study was 0.273 mCi/mg. Rats (n=50) 
received a single injection of 125I-BMP-6 at a dose 
level of 10 μg/kg with the activity of 20 µCi. 
Injection volume was 500 µl. Animals were 
sacrificed 30 min, 1, 3, 6 and 24 h following 
injection. Tissues were removed, weighted and 
radioactivity was measured in a gamma counter. 
The relative uptake of 125I-BMP-6 by tissues 
during time was expressed as nanograms of 125I-
BMP-6 per gram wet tissue weight.  
Western blot analysis of bone extracts from sham 
and OVX rats - Femur and tibia from sham and 
OVX rats were excised, flash-frozen in liquid 
nitrogen, and crushed into a fine powder with o 
biopulverizer (Biospec Products, Bartlesville, OK, 
USA). Two hundred grams of bone powder were 
extracted at 4°C with 4 M guanidine-HCl and a 
mixture of protease inhibitors (5 mM benzamide, 
0.1 M 6-aminohexanoic acid, 0.5 mM 
phenylmethylsulfonyl flouride, 5 mM N-
ethylmaleimide). The protein extract was then 
ethanol-precipitated and lyophilized. The pellet 
was dissolved in 6M urea, 50 mM Tris, pH 7.0, 
containing 0.15 M NaCl and purified by a heparin-
Sepharose column (Amersham Pharmacia 
Biotech). Bound proteins were eluted with 0.5 M, 
1 M and 2 M NaCl in 10 mM sodium phosphate 
buffer (pH 7) at flow rate of 1 ml/min. The protein 
eluted by 0.5 M NaCl was collected and dialyzed 
extensively against distilled water and 30% 
acetonitrile, 0.1% TFA at 4°C. SDS-PAGE was 
run on a 10% gel according to the method of 
Laemmli (18). Samples were heated in boiling 
water for 3 min with or without dithiothreitol (100 
mM) prior to electrophoresis. Following 
electrophoresis, the gel was blotted onto the 
nitrocellulose membrane and incubated with a goat 
polyclonal BMP-6 (Santa Cruz Biotechnology, 
CA), goat polyclonal BMP-2 (Santa Cruz 
Biotechnology, CA) and rabbit polyclonal BMP-7 
primary antibodies (19). Alkaline phosphatase- 
conjugated anti-rabbit and anti-goat were used as a 
secondary antibody. The membranes were 
developed with the chromogenic substrate 
(Invitrogen Corporation, Carlsbad, CA). 
In vivo and ex vivo bone mineral density (BMD) 
measurement by DXA -  At 6 week intervals the 
animals were scanned for bone density 
measurements by dual-energy X-ray 
absorptiometry (DXA; Hologic QDR-4000, 
Hologic, Waltham, MA) (20). At the end of the 
experiment, animals were anesthetized, weighed 
and killed by cervical dislocation. The hind limbs 
and lumbar vertebrae were removed and fixed in 
70% ethanol. The right femur and tibia, and the 
lumbar vertebrae (L1-5) were used for 
determination of the bone mineral content and 
BMD by DXA (21) equipped with a Regional 
High Resolution Scan software. The scan field size 
was 5.08 x 1.902 cm, resolution was 0.0254 x 
0.0127 cm, and the speed was 7.25 mm/s. The 
scan images were analyzed and the bone area, 
bone mineral content and bone density of whole 
bones, proximal and distal metaphyses and the 
shaft of femurs and tibiae were determined. 
PQCT - Isolated femurs were scanned by a 
peripheral quantitative computerized tomography 
(pQCT) X-ray machine (Stratec XCT Research M; 
Norland Medical Systems, Fort Atkinson, WI, 
USA) with software version 5.40. Volumetric 
content, density, and area of the total bone, 
trabecular, and cortical regions were determined as 
previously described (22, 23). 
MicroCT - The microcomputerized tomography 
apparatus (µCT 40) and the analyzing software 
used in these experiments were obtained from 
SCANCO Medical AG (Bassersdorf, Switzerland) 
(24). The distal femur was scanned in 250 slices, 
each 13 µm thick in the dorsoventral direction 
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(25). Three-dimensional reconstruction of bone 
was performed using the triangulation algorithm. 
The trabecular bone volume (BV, mm3), trabecular 
number (Tb. N, 1/mm), the trabecular thickness 
(Tb. Th, µm), and the trabecular separation (Tb. 
Sp, µm), were directly measured on 3D images 
using the method described by Hildebrand et al. 
(26). The trabecular bone pattern factor (TBPf) 
and the structure model index (SMI) were 
computed using software provided with the 
microCT machine (27,28).  
Histology and histomorphometry - Animals were 
given a subcutaneous injection of the 
fluorochrome calcein at 10 mg/kg (Sigma 
Chemical, St. Louis, MO) at 14 and 4 days before 
death. The femurs were removed at death, 
prepared for histomorphometric analysis and 
quantified using a computer-aided image analysis 
system (Bioquant II, R and M Biometrics, 
Nashville, TN) as previously described (29-31). 
Statistical analyses were performed using 
StatView 4.0 packages (Abacus Concepts, 
Berkeley, CA). Organs were taken for histologic 
analyzes, embedded in paraffin, cut in 10-µm-
thick sections, stained with hemalaun-eosin and 
toluidin blue to reveal potential therapeutic 
adverse effects. 
Biomechanical testing - Using a materials testing 
system (Model 810, MTS Systems Corp., 
Minneapolis, MN), two types of mechanical 
testing were performed on the femur. Three-point 
bending test of the femoral shaft was used to 
determine the mechanical properties of the 
midshaft femur. The midshaft of the femur was 
subjected to three-point bending to failure at a 
displacement rate of 0.1 mm/sec, as described by 
Turner and Burr (32), using a 2.5 kN load cell 
(MTS Model 661, 14A-03). The maximal load and 
stiffness were calculated from the load-
displacement curve. Indentation test of the distal 
femoral metaphysis was used to determine the 
mechanical properties of cancellous bone in the 
marrow cavity of the distal femoral metaphysis, as 
described previously (33,34).  
Biochemical serum and urine parameters - Serum 
bone formation and resorption markers were 
measured by commercially available kits. Serum 
concentration of osteocalcin was measured by 
ELISA using rat osteocalcin EIA kits (Biomedical 
Technologies Inc., Stoughton, MA). Serum 
concentration of C-telopeptide (CTx) was 
measured by ELISA using RatLaps ELISA kits 
(Nordic Bioscience Diagnostics, Herlev, 
Denmark). Osteoprotegerin (OPG) level in serum 
was measured by ELISA using Biomedica rat 
OPG ELISA kit (Biomedica, Wien, Austria). 
Serum concentration of IL-6 was measured by 
ELISA using IL-6 Quantikine ELISA kit (R&D, 
Minneapolis, MN) following procedures provided 
by the manufacturer. The minimum detectable 
concentration of osteocalcin, CTx, OPG and IL-6 
were 1ng/ml, 2 ng/ml, 0.73 pmol/l and 10 pg/ml, 
respectively. 
RNA isolation and PCR analysis - RNA was 
extracted with TRIzol (Gibco BRL, Grand Island, 
NY, USA) and cDNA was synthesized from 4 µg 
of total RNA with Superscript II Rnase H-Reverse 
Transcriptase as indicated by the manufacturer 
(Gibco BRL). Samples were amplified with 
AmpliTaq DNA polymerase (Perkin Elmer Roche, 
New Jersey, USA). Sequences of primers are 
shown in Table 1. Reactions were performed in a 
GeneAmp 4800 thermal cycler (Perkin Elmer 
Cetus, Emeryville, USA) for 32-40 cycles. Results 
were visualized by gel electrophoresis in 1% 
agarose (Seakem GTG, Bioproducts, Rockland, 
USA) in TAE buffer (TRIS HCl, acetic acid, 
EDTA, pH 8.0) and stained with ethidium bromide 
(Sigma, St. Louis, MO). 
Real time PCR - Two μg of purified total RNA 
from each rat bone were reverse transcribed with 
200 U of MMLV reverse transcriptase RNase (BD 
Biosciences) using random hexamer primers (final 
concentration 20 pmol per sample) according to 
the manufacture’s protocol. Gene expression of 
interest was measured using a commercial kit 
(LightCycler FastStart DNA Master SYBR Green, 
Roche Diagnostics, Mannheim, Germany) in the 
LightCycler instrument (Roche Diagnostics, 
Mannheim, Germany) as described (35). 
Sequences of primers are shown in Table 1. 
Expression of four housekeeping genes was 
analyzed and geNorm software was used to 
identify the most suitable reference gene. GAPDH 
transcripts were used as a normaliser. Results are 
represented as fold change of the comparative 
expression level.  
Statistical analysis - Distributions of quantitative 
data were tested with Kolmogorov-Smirnov test. 
Densitometric and histologic data measurement 
within the same time point were analyzed with 
One way ANOVA with one-sided Dunett-t post 
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hoc test against OVX and sham animals. Serum 
values of IL-6 were analyzed with paired t-test. 
Changes in gene expression were evaluated using 
One way ANOVA with one-sided Dunett-t post 
hoc test against OVX and sham animals. 
 
RESULTS 
 
Bone matrix from OVX rats is deficient in BMPs - 
Bone extracts from normal and OVX rats were 
analyzed by Western blot analysis following 
reduction with DTT (Fig 1A-C). Unlike bone 
extracts from normal rats, OVX animals had 
undetectable amounts of BMP-2, -6 and -7. (Fig 
1A-C), suggesting that E2 deficiency results with 
decreased amounts of BMPs in bone. This 
suggests that the lack of capacity of DBM from 
OVX rats to form new bone at an ectopic site in 
both normal and OVX rats may be at least in part 
due to BMP deficient DBM (1). 
Intravenously administered BMP-6 induces 
ectopic bone formation by binding to sc implanted 
extracted DBM from OVX rats – Systemic effects 
of BMP-6 were tested by iv injections following sc 
implantation of DBM from OVX rats into both 
normal and OVX rats. New bone formation was 
found 2 weeks later in an amount similar to the 
one induced by implanting DBM from normal rats 
(Figs 1F and G). These results suggest that, 
following systemic administration of BMP-6, 
DBM from OVX rats, lacking new bone induction 
capacity, regained the osteogenic potential in both 
normal and OVX rats. A similar result was 
obtained when 8M urea extracted and thus non-
osteogenic DBM from normal rats was implanted 
sc into male rats injected iv from day 2-5 with 100 
μg/kg BMP-6 (data not shown). These results 
prompted us to test whether systemic 
administration of BMP-6 is effective in restoring 
bone volume in aged rats, 12-18 months following 
OVX. 
Pharmacokinetics and biodistribution of 
systemically administered 125I-BMP-6 - Prior to 
testing the efficacy of BMP-6 on the skeleton we 
tested its pharmacokinetic properties and 
biodistribution. High serum levels of  125I -BMP-6 
were achieved immediately after iv injection 
followed by a steady decline (Fig 1D). 
Approximately 60 ng BMP-6/ml was present in the 
circulation 1 min after injecting a dose of 10 µg 
BMP-6/kg. Biodistribution of 125I-BMP-6 in the 
rat kidney increased during the first 4 h following 
injection, and decreased in the following 20 h, 
while the level of 125I-BMP-6 in the liver increased 
immediately and decreased slowly throughout the 
experiment. The uptake of 125I-BMP-6 in femur 
was 0.15% of the total applied dose 
(approximately 4.5 ng 125I-BMP-6), reached the 
maximal value at 4 h and then declined slowly to 
0.05% of the applied dose at 24 h following 
injection (Fig 1C). The maximal uptake of 125I-
BMP-6 in the tibia was 0.12% of the applied dose 
(approximately 3.6 ng 125I-BMP-6) at 8 h 
following injection and declined slowly to 0.025% 
of the applied dose at 24 h following injection (Fig 
1E). Autoradiographic analysis demonstrated that 
125I-BMP-6 remained intact in the serum, assayed 
at 4 h after administration (data not shown). 
E2 specifically induces expression of BMP-6 
mRNA in MC3T3-E1 preosteoblastic cells  in vitro 
- Prior to use of E2 as a positive control in these 
studies we sought to confirm its specific effect on 
BMP-6 mRNA expression in osteoblastic cells in 
vitro. MC3T3-E1 pre-osteoblasts express BMP-2 
and -4 during differentiation and in vitro bone 
formation (3). Addition of E2 to cell cultures 
suppressed the expression of BMP-2 and BMP-4, 
but specifically induced the expression of BMP-6 
transcripts in a dose-dependant manner (Fig 1H). 
The number of bone nodules on day 27 of culture 
were not affected (data not shown). E2 induced 
BMP-6 was thus capable to replace the function of 
BMP-2 and BMP-4 in in vitro osteogenesis. 
Moreover, upon E2 treatment, the expression 
profile of specific BMP receptors by MC3T3-E1 
cells changed. Besides ALK-3 and ALK-6, 
MC3T3-E1 cells treated with E2 expressed ALK-2 
receptor, a specific BMP type I receptor reported 
to be preferentially used by BMP-6 in osteoblasts 
(data not shown).  
BMP-6 restores bone volume in OVX rats - 
Twelve months following OVX rats were treated 
for three months with BMP-6 and the BMD was 
fully restored (Fig 2). Within 6 weeks of treatment 
rats regained the lost BMD and at 12 weeks 
following therapy they had higher hind limb 
(femur and tibia) BMD as compared to OVX, E2 
treated and sham animals (9%, 6% and 3% 
increase, respectively) (Fig 2). There were no 
significant differences between BMP-6 doses of 
10, 25 and 50 μg/kg. Within the 12 week period 
hind limb BMD of sham treated rats decreased by 
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2%. BMD of the lumbar spine showed an increase 
of 9% at 12 weeks following BMP-6 treatment 
(data not shown).  
Ex vivo BMD values of tibiae, femurs and 
vertebrae increased for 8-11% in rats treated with 
BMP-6, independently of a dose used. E2 was 
about four times less effective than BMP-6 in 
restoring BMD (data not shown).  
pQCT analyses of femurs showed that the 
total BMD was 13.8% higher and the total femoral 
bone mineral content (BMC) was about 18% 
higher in BMP-6 treated rats as compared to OVX 
rats. Cortical BMC was higher for 24%, cortical 
bone mineral area for 21% and the cortical 
thickness for 28% as compared to OVX rats 
(Table 2). Cortical bone parameters in femurs 
were preferentially enhanced over the trabecular 
bone by BMP-6 treatment (Table 2). Analyses of 
the tibiae showed a similar pattern, confirming a 
greater effect of BMP-6 on the cortical bone of the 
appendicular skeleton (data not shown).   
MicroCT analyses of distal femurs showed 
that the bone volume (BV/TV) of rats treated with 
10 μg BMP-6 was 78% increased compared to 
OVX control animals and 47% increased 
compared to rats receiving E2 (Fig 3 and 4A). The 
trabecular number was higher 38% in BMP-6 and 
19% in E2 treated rats (Fig 4B). The trabecular 
thickness was increased 35% in BMP-6 treated as 
compared to OVX rats, and was 28% and 11% 
higher than in E2 treated and sham animals 
respectively (Fig 4C). The trabecular separation 
was decreased 36% in BMP-6 treated rats (Fig 
4D). Surprisingly, BMP-6 therapy increased the 
connectivity density for 33% (Fig 4E) and 
decreased the structure model index (SMI) for 
42% (Fig 4F). Connectivity parameters were 38% 
better then in E2 treated animals. However, none 
of the treatments were fully effective at restoring 
cancellous bone architecture and volume of sham 
rats. MicroCT analysis of the 5th lumbar vertebra 
showed 25% increased BV/TV, 8% increased 
trabecular number, 16% increased trabecular 
thickness and 29% decreased trabecular separation 
in BMP-6 treated rats (Table 3). This suggested 
that the trabecular bone of the lumbar vertebrae 
responded better, reaching almost the values of 
sham animals, to the systemic administration of 
BMP-6 as compared to long bones.  
The three-point bending test was used to 
determine the mechanical properties of the 
midshaft femur. Maximal load and stiffness were 
32% and 23% higher in BMP-6 treated animals as 
compared to OVX rats. Bones from BMP-6 treated 
animals absorbed 33% more energy than in sham 
animals (Table 4). Toughness was increased by 
22% in BMP-6 treated rats as compared to sham 
rats (Table 4). The indentation test was used to 
determine the mechanical characteristics of 
trabeculae of the distal femoral metaphyses. Direct 
parameters: maximal load, stiffness and energy 
absorbed were increased about three to four fold in 
BMP-6 treated rats as compared to OVX control 
animals (Table 4). The ultimate strength showed 
the same trend. BMP-6 treatment improved the 
trabecular bone parameters as compared to OVX 
animals, but did not restore the mechanical 
properties to those exhibited by sham rats. 
Histomorphometric analyses showed that 
the bone volume and the trabecular thickness of 
distal femurs were higher for 78% and 35%, 
respectively, in BMP-6 treated animals (Fig 3). 
Dynamic bone parameters showed increased 
mineral apposition rate for 48% and bone 
formation rate/bone volume for 18% in BMP-6 
treated rats, while E2 decreased the bone formation 
rate by 39% (Fig 5). Most importantly, BMP-6 
both increased the osteoblast surface for 32% and 
decreased the osteoclast surface for 29%. E2 
decreased the osteoclast surface for 43% but did 
not have an effect on the osteoblast surface (Fig 
5). Improved bone formation rates and mechanical 
properties of BMP-6 treated bones resulted from 
both increased number of osteoblasts and from 
potentially increased extracellular matrix 
production over E2 therapy (Table 4, Fig 5 and 6).  
 The body weights in this experiment 
didn’t change until day 375. Later, the body 
weight of BMP-6 treated rats was 22% higher then 
in those receiving E2 and 11% higher then in sham 
animals, but was not different from OVX rats 
(data not shown). 
 Autopsy did not reveal any treatment-
related gross pathology. Organ weights were 
normal, only rats treated with E2 or E2 and BMP-6 
had increased uterine weights (data not shown). 
Histopathological findings of heart, lung, liver, 
spleen, kidney, uterus, pancreas, oesophagus, 
stomach, intestine, lymph nodes, bladder, brain, 
eyes, aorta, trachea, skeletal muscle, bone marrow 
(sternum) and femur were normal. Beyond 
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calcification of the tail at the site of BMP-6 
injection no adverse effects were observed.  
BMP-6 and E2 do not act synergistically on 
increasing bone volume in OVX rats - Rats treated 
with E2 at twelve weeks following therapy had 
similar femur BMD values as OVX control 
animals (Table 2). When both BMP-6 and E2 were 
given to OVX rats BMD values at 12 weeks 
increased for 14%. However, BMD in rats treated 
with E2 and BMP-6 was not different from rats 
treated with BMP-6 alone (Table 2). E2 had no 
effect on cortical and trabecular thickness, while a 
combination of E2 and BMP-6 increased the 
cortical thickness by 22% without an effect on the 
trabecular thickness (Table 2, Fig 4). These results 
suggest that E2 alone did not have an effect on the 
bone in aged OVX rats unless combined with 
BMP-6.  
Effects of BMP-6 on femoral gene expression - At 
three months following BMP-6 therapy the 
expression of ALK-2 and ALK-6, BMP receptors, 
as well as Smad 5, a downstream molecule in the 
BMP signaling pathway was increased (Fig 6). E2 
reduced the expression of ALK-2 and -6 and had 
no effect on Smad 5 (Fig 6). BMP-2 and BMP-3 
expression was increased following OVX and was 
suppressed by both BMP-6 and E2 therapy (Fig 6). 
On the other hand, OVX reduced the expression of 
BMP-6 in femurs, while E2 increased the BMP-6 
expression (Fig 6). BMP-4 expression was 
unchanged with both BMP-6 and E2 treatment. 
Furthermore, BMP-6 increased the expression of 
alkaline phosphatase and collagen type I, reducing 
the expression of osteopontin (Fig 6).  Expression 
of BMP antagonists, chordin and cerberus was 
decreased in rat femurs treated with BMP-6. The 
expression of twisted gastrulation was decreased 
following OVX and increased to normal levels 
following BMP-6 therapy (Fig 6). On the contrary, 
the expression of noggin was increased following 
OVX, BMP-6 therapy further increased the noggin 
expression, while E2 had no effect (Fig 6).  
Serum biochemical parameters- BMP-6 treatment 
at a dose of 10 µg/kg/3xweek increased the serum 
osteocalcin level, a bone formation marker, as 
compared to OVX animals, while E2 did not have 
an effect (Fig 7A). Serum C-telopeptide values 
were lower in rats treated with BMP-6 indicating 
that BMP-6 suppressed the activity of osteoclasts 
(Fig 7B). Furthermore, BMP-6 increased the OPG 
serum levels as compared to OVX animals (Fig 
7C), which may correspond to lower osteoclast 
numbers in BMP-6 treated rats (Fig 5). BMP-6 
may, thus, increase the bone formation and 
suppress the bone resorption, which may in part 
explain its anabolic bone effect.  
BMP-6 suppresses expression of IL-6 in spleen 
and IL-6 serum levels - BMP-6 decreased IL-6 
serum levels 72 h following a single iv injection 
(Fig 8A). Three BMP-6 injections reduced the 
expression of IL-6 in the spleen to undetectable 
values as compared to OVX rats (Fig 8B) 
suggesting an additional mechanism by which 
BMP-6 might mediate the osteoclast production.  
Maintenance of bone in OVX rats pre-treated by 
BMP-6 - To further explore whether the newly 
formed bone following BMP-6 therapy was 
maintained, BMP-6 was given to aged OVX rats 
for 12 weeks and was then discontinued. Animals 
were divided into three groups: untreated, treated 
with E2 and those continuing the BMP-6 therapy. 
BMD was then monitored at 6, 12, 18, 24 and 30 
weeks (Fig 9). BMP-6 therapy throughout the 
treatment period of 7.5 months increased the hind 
limb BMD values as compared to both OVX and 
sham rats which lost about 4% of BMD from the 
beginning of treatment (Fig 9). Hind limb BMD 
values in animals treated with BMP-6 were about 
8% higher at 18 weeks than at 12 weeks, and 
about 14% higher as compared to OVX rats, while 
at 24 and 30 weeks BMD did not change any more 
(Fig 9). In rats treated with E2 following the initial 
BMP-6 therapy BMD gains were maintained. 
Animals without any therapy maintained the BMD 
values until 24th week and then showed a decline 
to values still 10% higher than in OVX control rats 
(Fig 9). We suggest that animals that discontinued 
the BMP-6 therapy maintained the BMD gains for 
another 12 weeks while treatment with E2 
maintained the BMD until the termination of the 
study. 
Ex vivo BMD values of the excised femur, tibia 
and lumbar vertebrae were similar to the in vivo 
results (data not shown). 
Less frequently administered low BMP-6 dose is 
the most efficacious in increasing bone volume in 
OVX rats - In search for the most effective BMP-6 
dose, aged OVX rats 18 months following OVX 
were administered BMP-6 less frequently at lower 
doses. Six weeks following the beginning of 
therapy BMP-6 treated animals showed higher 
BMD of hind limbs as compared to both OVX and 
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sham animals (Fig 10). Within 6 weeks 1 
µg/kg/3xweek of BMP-6 increased the hind limb 
BMD for 11%. Doses of 10 µg/kg 1x/week and 
3x/week increased the BMD for 9% and 8%, 
respectively (Fig 10). Surprisingly, aged rats 
gained the bone volume in an amount similar to 
young animals treated with BMP-6 (data not 
shown), although at the termination of the study 
the age difference was 2 years (Fig 10). This 
suggests a complex biology at the local bone tissue 
site perhaps requiring a recovery time needed to 
maximize the receptiveness of osteoblasts to the 
intermittent exposure of BMP-6.  
  
DISCUSSION 
 
In these studies we show that systemically 
administered BMP-6 in aged OVX rats has a 
pronounced anabolic effect significantly 
improving the bone quality. Both in vivo and ex 
vivo bone densitometric measurements revealed 
that BMP-6 restores trabecular bone of the axial 
skeleton and the cortical bone, while only a partial 
restoration of the trabecular bone occurs in long 
bones. The maximal load, stiffness and energy 
absorbed were increased about three to four fold in 
BMP-6 treated rats. Therapy with BMP-6 reduces 
serum C-telopeptide and IL-6, while increasing 
serum osteocalcin and osteoprotegerin levels, 
suggesting uncoupling of bone formation from 
bone resorption.  
Not only hormones, like E2 and PTH, have 
different effects on the peripheral and axial 
skeleton. For example, mutations of the cartilage-
derived morphogenetic protein-1 (CDMP-1; GDF-
5; BMP-14) cause Hunter-Thompson and Grebe 
chonrodysplasia (36,37). Both diseases are 
characterized by severe shortening of the limbs 
and multiple defects of limb joints and the normal 
axial skeleton (36,37). Grebe chondrodysplasia is 
caused by a point mutation in a Cdmp-1 gene, 
while in Hunter-Thompson chondrodysplasia there 
is an insertion in the mature domain leading to 
non-functional CDMP-1 protein. 
So far the parathyroid hormone (PTH) is 
the only approved anabolic bone agent, which 
increases the trabecular bone volume, but may 
decrease the cortical bone mass (38) and produce 
cortical resorptive tunnels (39). PTH in aged OVX 
rats restores the bone volume by thickening the 
existing trabeculi without increasing the trabecular 
connectivity (40,41), although not influencing the 
trabecular mechanical strength (42). PTH also 
improves rigidity and stiffness of bone, but makes 
them more brittle, with less elasticity and less 
deformation before fracture (43). BMP-6 improves 
the trabecular microarchitecture in aged OVX rats 
by increasing the trabecular thickness, trabecular 
number and in particular the trabecular 
connectivity. BMP-6 also increases elasticity and 
energy absorbed. After discontinuation of the 
BMP-6 therapy animals maintained the BMD 
value for another 12 weeks. In comparative studies 
utilizing aged rats with similar post OVX time 
period, PTH withdrawal results in a loss of 
acquired BMD within 5 weeks (44). Unlike PTH, 
which circulates in serum, BMP-6 circulates when  
bone regenerates, like in patients with multiple 
bone fractures (Grgurevic et al, in preparation). 
This excludes other BMPs as potential circulating 
candidates in the regeneration of the skeleton 
including osteoporosis (Grgurevic et al, in 
preparation). 
BMP-6 exerts its effects on bone via 
promoting bone formation and reducing bone 
resorption thereby providing a distinct means to 
accumulate the bone tissue mass. No known 
therapeutic agent achieves both effects by in vivo 
systemic administration. The currently available 
resorption inhibitors (E2 and related compounds, 
bisphosphonates and calcitonin) have little effect 
on bone formation over a prolonged periods of 
time (45). It has been recently shown that leptin 
has a direct positive effect on the osteoblastic 
differentiation of stromal cells, and may also 
modulate bone remodeling by inhibiting the 
expression of receptor activator of nuclear factor κ 
B ligand (RANKL), the major downstream 
cytokine controlling the osteoclastogenesis in 
human stromal cells (46). However, the systemic 
effect of exogenously administered leptin on BMD 
has never been demonstrated. BMP-6 
administration increases the bone formation, and 
in parallel increases OPG serum levels, 
uncoupling the osteoblast from osteoclast activity, 
leading to bone gain at both trabecular and cortical 
bone compartments.  
IL-6 as a single molecule plays an 
important role in the pathophysiology of 
postmenopausal osteoporosis (47). We therefore 
studied its availability in BMP-6 treated rats and 
found that BMP-6 decreases the level of IL-6 in 
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serum and more importantly its expression in the 
spleen, as one of important organs for IL-6 
synthesis. Recently, we and others have also 
shown that BMP-6 significantly reduces IL-6 
production from marrow stroma and 
gastrointestinal system in rats (48,49). E2 can also 
inhibit IL-6 expression via an E2 receptor mediated 
transcriptional activity (49), which is supported by 
the fact that E2 depletion results in IL-6 
upregulation (51).   
We and others (10) have suggested that E2 
induced osteogenesis is associated with increased 
levels of BMP-6 mRNA in mouse femurs, 
reflecting the emergence of clusters of BMP-6 
positive stromal cells adjacent to active bone 
formation surface. We show that addition of E2 to 
BMP-6 therapy has no a synergistic effect on 
BMD and the bone volume which may, at least in 
part, suggest a BMP-6 requirement for E2 bone 
activity. On the other hand, E2 maintained the 
gained BMD after discontinuation of BMP-6 
prolonged therapy.  It was suggested that E2 
specifically upregulates BMP-6 mRNA in 
osteoblastic cell lines (8). BMP-6 and E2 crosstalk 
might be Wnt-mediated since BMPs are essential 
for Wnt-induced osteoblast differentiation (52), 
and Wnt signaling is also critical for the effects of 
E2 on bone (53). Another example involves the 
transient upregulation of Cbfa-1 in response to 
BMP (54) and its’ affection by E2-OPG pathway 
(54). It has been also shown that E2 prevents bone 
loss through a TGFβ-dependent mechanism, and 
that TGFβ signaling in T cells preserves bone 
homeostasis by blunting the T cell activation 
(56,57). However, a systemic effect of TGFβ on 
bone in animal models of osteopenia has not yet 
been studied. 
Apart from BMPs, several other factors 
important for osteogenesis have been investigated 
in animal models of osteopenia. Basic FGF 
improves trabecular connectivity in aged OVX rats 
by increasing osteoid accumulation on trabecular 
surfaces and in between perforated trabecular rods 
(41). Like BMP-6, bFGF improves trabecular 
connectivity (58,59) but, as a general mitogen with 
serious adverse side-effects, its systemic 
administration is not practical (42,58). Human 
growth hormone (hGH) and insuline like growth 
factor I (IGF-I) in a rat model of osteopenia 
increase bone size and mineral content but 
decrease the BMD (59). Their effects on bone are 
currently investigated in clinical trials (59). 
Numerous studies have demonstrated that 
BMPs are involved in local bone formation via 
stimulating proliferation and chemotaxis of bone 
progenitor cells, angiogenesis during development 
and bone repair, and endochondral osteogenesis by 
stimulating osteogenic compartment of bone 
stromal cells (2,3,60-63). It was never 
demonstrated that BMPs systemically targets bone 
marrow stem cells. Based on findings that BMP-6 
successfully promotes restoration of bone in young 
and aged osteopenic rats, we suggest that it targets 
bone marrow stem cells which do not loose a self 
renewal and differentiation characteristics by 
ageing. However, it has been demonstrated that 
the amount of stem cells decreases by advanced 
age in both rats and men (64).  
Apart from bone formation at the site of 
injection no side effects were observed by long 
standing systemic administration of BMP-6. Of 
particular interest is the fact that systemically 
administered BMP-6 influences bone formation at 
endosteal, periosteal, and trabecular bone 
compartment. 
Among genes analyzed BMP-3 is of 
particular interest. Its upregulation following OVX 
and suppression by BMP-6 might be important 
since it has been suggested that BMP-3 is a 
negative regulator of in vitro and in vivo 
osteogenesis (65). BMP-3 inhibited alkaline 
phosphatase production induced by BMP-2 in 
vitro and BMP-3 knock-out mice had about twice 
the trabecular bone volume as wild-type controls 
(65). We have previously demonstrated that 
changes in BMP-3 and ALK-2 expression are 
reduced by mechanical loading which enables the 
induction of cartilage in a bone chamber (66). 
Treatment by BMP-6 might have inhibited BMP-3 
expression and activity by formation of inactive 
BMP-3 heterodimers, but also inhibiting the effect 
of the BMP-3 homodimer.  
Collectively, these results show, for the 
first time, that systemically administered BMP-6 
restores bone volume and quality in osteoporotic 
rats making it a feasible candidate for treating 
osteoporosis in patients with pronounced bone 
loss. 
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FIGURE LEGENDS 
 
Figure 1. A-C, Western blot analyses of bone extracts from normal rats show BMP-2, BMP-6 and BMP-7 
at 35 kDa before and at 17 kDa after reduction with DTT. OVX animals had undetectable amounts of 
BMP-2, BMP-6 and BMP-7. Fractions following purification with the heparin sepharose chromatography 
were precipitated with SAS and subjected to SDS-PAGE and immunoblotting. Lanes 1 and 2 BMP-2, 
BMP-6 or BMP-7 protein standard (0.5 µg) -/+ DTT; lane 3 molecular mass marker; lanes 4 and 5 sham 
bone extract fraction of 0.5M NaCl -/+ DTT; lanes 6 and 7 OVX bone extract fraction of 0.5M NaCl -/+ 
DTT. Arrows indicate the mature BMP dimer and monomer of BMP of 35 (►) and 17 kDa (Î). Bands 
were visualized with specific BMP-2,-6,-7 antibodies. M: molecular mass marker. D, pharmacokinetic 
properties of iv injected 125I-BMP-6 and E, biodistribution of 125I-BMP-6 in femur and tibia; F, histology 
of OVX DBM implanted into a normal animal; G, histology of DBM from OVX rats implanted into 
normal rat and treated with BMP-6 showing new bone formation (toluidin blue staining, 25x 
magnification); H, RT-PCR analysis of BMP-6, -4 and -2 expression in MC3T3-E1 cells treated with E2. 
Samples were normalized to GAPDH expression.  
 
Figure 2. In vivo hind limb BMD in aged rats treated with BMP-6 (50 μg/kg) and E2 (50 μg/kg). Within 6 
weeks of treatment rats regained the lost BMD and at 12 weeks following therapy they had higher hind 
limb BMD as compared to OVX, E2 treated and sham animals. O, significantly different from OVX and 
E, significantly different from animals treated with E2 (by ANOVA Dunnett test, P<0.05); mo, months, 
TH, therapy. 
 
 
Figure 3. μCT longitudinal and horizontal as well as histological analyses of distal femurs in aged rats 
treated with E2 (50 μg/kg), BMP-6 (10 μg/kg) and E2 (50 μg/kg) + BMP-6 (10 μg/kg) for 3 months 
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following 12 months of OVX. BMP-6 alone and in combination with E2 increased the trabecular bone 
volume and connectivity. The standardized region of interest for μCT  analyses began 4 mm above the 
intercondylar fossa and included 50 slices. 
 
Figure 4. µCT analyses of the distal femur in aged OVX rats treated with E2 (50 μg/kg), BMP-6 (10 
μg/kg) and E2 (50 μg/kg) + BMP-6 (10 μg/kg) for 3 months following 12 months of OVX. BMP-6 
increased trabecular bone volume (BV/TV), trabecular number (Tb. N), trabecular thickness (Tb. Th) and 
connectivity density (ConnD). BMP-6 decreased trabecular separation (Tb. Sp) and structural model 
index (0-plate to 3-rode) (SMI) as compared to control group (OVX). O, significantly different from 
OVX, E, significantly different from animals treated with E2, and EB, significantly different from BMP-6 
+E2 treated animals (by ANOVA Dunnett test, P<0.05). 
 
Figure 5. Dynamic histomorphometry of the distal femur in aged OVX rats treated with E2 (50 μg/kg)  
and BMP-6 (10 μg/kg). Animals were treated for 3 months following 12 months of OVX (Figure 2). 
BMP-6  increased mineral apposition rate (MAR), bone formation rate/bone volume (BFR/BV) and 
osteoblast surface as a percentage of bone surface (Ob.S/BS) and decreased osteoclast surface as a 
percentage of bone surface (Oc.S/BS) compared to OVX group of rats. O, significantly different from 
OVX, and S, significantly different from sham gorup of animals (by ANOVA Dunnett test, P<0.05). 
 
Figure 6. PCR analyses of rat femurs treated for three months with BMP-6 and E2. BMP-6 decreased the 
expression of BMP-2, BMP-3, osteopontin (OPN), chordin and cerebrus; increased the expression of 
BMP-6, ALK-2, ALK-6 Smad 5, alkaline phosphatase (AP), collagen I (COL I), twisted gastrulation 
(Tsg) and noggin; and did not change the expression of BMP-4. E2 (50 µg/kg) completely suppressed the 
expression of ALK-2 and -6 and had no effect on Smad 5 in aged OVX rats. OVX reduced endogenous 
expression of BMP-6, while E2 increased BMP-6 expression. The fold change (FC) of gene expression 
obtained by real time PCR is shown below the gel images. Molecular marker (Mm) is shown in the first 
line of the gel and molecular weight of PCR products is indicated on the right side of the image (base 
pairs, bp). O, significantly different from OVX control rats (p<0.05, ANOVA, Dunnett test). 
 
Figure 7. Serum values of osteocalcin (Oc), C-telopeptides (Ctx) and osteoprotegerin (OPG). Three 
months of BMP-6 (10 μg/kg) therapy increased the levels of Oc (A) and OPG (B) and decreased the levels 
of Ctx (C) in serum of aged rats 12 months following OVX; O, significantly different from OVX control 
rats (p<0.05, ANOVA, Dunnett test).  
 
Figure 8. A, Decreased serum IL-6 levels 72 h following a single injection of BMP-6 (10 μg/kg); B, 
Semiquantitative RT-PCR analyses showed reduced IL-6 and β-actin expression in the spleen of rats 
treated for 7 days with BMP-6 (10 µg/kg/3xweek) as compared to OVX rats.  
 
Figure 9. In vivo hind limb BMD in aged rats initially treated with BMP-6 (10 μg/kg) for 3 months and 
then subdivided into groups that continued BMP-6 (10 μg/kg) or E2 (50 μg/kg) treatment for the following 
4.5 months and the third group that discontinued the initial BMP-6 therapy. Rats that discontinued the 
BMP-6 therapy maintained the BMD gains until the 24th week, while rats continuing the BMP-6 therapy 
increased BMD values for another 8%. Rats treated with E2 after 12 weeks of initial therapy with BMP-6, 
maintained the gained BMD until the end of experiment at week 30. O, significantly different from OVX, 
and S, significantly different from sham gorup of animals (by ANOVA Dunnett test, P<0.05). 
 
Figure 10. In vivo hind limb BMD of 26.5 months old rats treated with low doses of BMP-6 for 1.5 
months, 18 months following OVX. Six weeks following the beginning of therapy BMP-6 treated animals 
showed higher BMD values of hind limbs as compared to both OVX and sham animals. BMP-6 at a dose 
of 1 µg/kg three times a week was most effective in restoring BMD. O, significantly different from OVX, 
gorup of animals (by ANOVA Dunnett test, P<0.05). 
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Table 1. Sequences of primers used for gene expression analysis.  
 
Target gene Semi-quantitative PCR Real time PCR 
IL-6 F CAAGAGACTTCCAGCCAGTTGC 
R TTGCCGAGTAGACCTCATAGTGAC 
 
BMP-2 
 
    mouse 
F GCAGAGCTCCAGATTTTTCG 
R TTAAGACGCTTCCGCTGTTT  
F GTTCCCTACAGGGAGAACACC 
R GCCTGCGGTACAGATCTAGC 
 
F TGAACACAGCTGGTCTCAGG 
R TTAAGACGCTTCCGCTGTTT 
 
BMP-3 F CACTCAGCTCTTACGGAAGGCC 
R CTGTTTCTTTTTGCTCCGGCTC 
F TGCTGTGGCTCTATGACAGG  
R TGGTGTTCACCAATTCTCCA 
BMP-4 
 
    mouse 
F TTCCTGGTAACCGAATGCT 
R GGGGCTTCATAACCTCATAA  
F TTCCTGGTAACCGAATGCT 
R GGGGCTTCATAACCTCATAA 
 
F TCTGGTCTCCGTCCCTAATG 
R AAACTTGCTGGAAAGGCTCA 
 
BMP-6 
 
    mouse 
F AGGATGGGGTGTCAGAGGGAGA 
R GTTGTGCTGCGGTGTCACCA 
F CAGGAGCATCAGCACAGAGA 
R ATGTGTGCGTTGAGTGGGA 
 
F TTCTTCAAGGTGAGCGAGGT 
R TAGTTGGCAGCGTAGCCTTT 
 
ALK-2 F CCACCAACGTCGGAGATAGCA 
R TGCAGCACTGTCCGTTCTTCTT 
F ACCACCAACGTCGGAGAT 
R CCCCTCCACACTTCTCCATA 
ALK-6 F CAGGTATAAAAGACAAGAAGCCAG 
R TCTCTCATGTCCTCATAAGAAGGG 
F CTCTGGGAGATTGCAAGGAG 
R TCATAAGCTTCCCCATTTGC 
Smad 5 F TGATGAGGAAGAGAAATGGG 
R GGAGGATAGGGGCTGTTAGG 
F  GAATGCCACGTTTCCTGATT 
R AGGGGTATCAGCTGGGAGTT 
AP F CGACACGGACAAGAAGCCCT 
R AAGGTTGGCTCCAATGCAGG 
F CCTTGAAAAATGCCCTGAAA 
R CTTGGAGAGAGCCACAAAGG 
Osteopontin F GTGAACTCGGATGAATCTGACG 
R CTTGTCCTCATGGCTGTGAAAC 
F ATGGCTTTCATTGGAGTTGC 
R GAGGAGAAGGCGCATTACAG 
Collagen type I F TATTGCTGGTGCTCCTGGCTTC 
R TCACCACGGGCTCCTCGTTT 
F TGCTGCCTTTTCTGTTCCTT  
R AAGGTGCTGGGTAGGGAAGT 
Chordin F GAACATCAAACCTCAGTGCCCC 
R TGTGAACCGAACCCTGCTGG 
F CCAGGGACAGCTACTTCGAG 
R AGAGGACGCTTTGAAGGACA 
Cerberus F TGGCATCGCTTCATGTTCAGA 
R GTTCCGTCTTCACCATGCACTG 
F ACTGCTCACCCACCAAATTC 
R AGCTGGGAGTCCAGAGATGA 
Tsg F TCCCTGATGTTCCTGATGTGCC 
R CCGAGGGTTGCACATACCGA 
F TGTGAGCAAGTGCCTCATTC 
R GGGAGGTGTGTCGCTGTAAT 
noggin F GAGCAAGAAGCTGAGGAGGA 
R GTGGGGATCCATCAAGTGTC 
F CCTGGCTTTCTGGTTCATGT 
R GCCGGGTAACTTTTGACGTA 
GAPDH 
 
F ACCACAGTCCATGCCATCAC 
R TCCACCACCCTGTTGCTGTA 
F AGACAGCCGCATCTTCTTGT 
R CTTGCCGTGGGTAGAGTCAT 
 
All primers are for rat gene sequences; mouse primers were used for analyses of MC3T3 cell line in in 
vitro experiments.  
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Table 2.  pQCT of the distal femur in aged OVX rats treated with BMP-6 and E2
 
 
 
 
Groups 
 
Treatment 
 
 
Total BMD 
(mg/mm2) 
 
Total BMC 
(mg) 
 
Total area 
(mm2) 
 
Cortical BMD 
(mg/mm2) 
 
Cortical th. 
(mm) 
 
1. 
 
Sham  
 
  
743.7 ± 43.7 O
 
14.3 ± 3.2 O
 
19.2 ± 5.6 
 
995.9 ± 87.2 O
 
0.80 ± 0.07 O, E
 
2. 
 
OVX  
 
 
587.7 ± 38.3 
 
11.3 ± 2.8 
 
19.2 ± 3.2 
 
945.5 ± 91.3 
 
0.58 ± 0.04 
 
3. 
 
OVX + E2
 
 
625.5 ± 41.4 
 
12.6 ± 2.9 
 
19.5 ± 4.2 
 
974.3 ± 102.3 
 
0.67 ± 0.04 
 
4. 
 
OVX + BMP-6 
 
 
667.2 ± 50.8 O
 
13.3 ± 3.6 O 
 
20.0 ± 4.9 
 
1007.7 ± 106.5 O  
 
0.74 ± 0.06 O 
 
5. 
 
OVX + BMP-6+E2  
 
670.8 ± 55.3 O
 
13.4 ± 3.8 O
 
19.9 ± 5.3 
 
1014.4 ± 100.9 O
 
0.71 ± 0.05 O
 
 
Animals were treated for 3 months following 12 months of OVX (Figure 2); n=10 in all groups 
Parameters analyzed include: Total BMD – bone mineral density, Total BMC – bone mineral content, Total area, Cortical BMD – bone mineral 
density and Cortical th. – thickness 
Data are mean ± SEM, O significantly different from group 2 (by ANOVA Dunnett test, P<0.05) 
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Table 3. Bone volume and trabecular microarchitecture of 5th lumbar vertebrae in aged OVX rats  
  treated with BMP-6 and E2 by µCT 
 
 
 
Groups 
 
Treatment 
 
 
BV/TV 
(%) 
 
Tr. Nm 
 (1/mm) 
 
Tr. Th  
(mm) 
 
Tr. Sp 
(mm) 
 
1. 
 
Sham  
 
0.79 ± 0.07 O 2.56 ± 0.30 0.35 ± 0.08 O 0.18 ± 0.03 O, E
 
2. 
 
OVX  
 
0.65 ± 0.08 2.51 ± 0.15 0.25 ± 0.04 0.21 ± 0.04 
 
3. 
 
OVX +E2
 
0.75 ± 0.06 2.71 ± 0.08 0.28 ± 0.03 0.18 ± 0.02 
 
4. 
 
OVX + BMP-6 
 
0.82 ± 0.07 O 2.81 ± 0.38 O 0.30 ± 0.04 O 0.14 ± 0.02 O, E
 
Animals were treated for 3 months following 12 months of OVX (Figure 2); n=10 for all groups 
Parameters analyzed include: BV/TV – trabecular bone volume, Tb. N – trabecular number, Tb. Th – trabecular thickness, Tb. Sp – trabecular 
separation  
Data are mean ± SEM, O significantly different from group 2 and E significantly different from group 3 (by ANOVA Dunnett test, P<0.05) 
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Table 4. Biomechanical parameters of the femur from BMP-6 treated aged, OVX rats 
 
 
                                    Three Point Bending Test                                                                    Indentation Test  
 
 
Parameters 
 
Sham  
 
 
OVX 
 
 
OVX + BMP-6 
 
 
Parameters 
 
Sham  
 
 
OVX  
 
 
OVX + BMP-6  
 
 
Fu (N) 
 
 
213.5 ± 9.2 O
 
168.9 ± 5.4 
 
223.2 ± 5.9 O
   
  Fu (N) 
 
 
37.3 ± 7.9 O
 
3.3 ± 0.8 
 
13.5 ± 3.9 O, S
 
S (N/mm) 
 
 
806.8 ± 46.5 O
 
646.7 ± 52.1 
 
793.0 ± 38.1 O
  
  S (N/mm) 
 
 
177.0 ± 66.1 O
 
20.0 ± 4.1 
 
83.3 ± 26.1 O
 
W (mJ) 
 
 
49.2 ± 4.2 O
 
39.6 ± 3.5  
 
65.6 ± 4.8 O, S
  
  W (mJ) 
 
 
6.8 ± 1.2 O
 
0.6 ± 0.2 
 
2.4 ± 0.8 O, S
 
T (MJ/m3) 
 
 
4.3 ± 0.3 O
 
3.9 ± 0.4 
 
5.3 ± 0.3 O, S
  
  σ (N/mm2) 
 
 
19.8 ± 4.2 O
 
1.8 ± 0.4 
 
7.1 ± 2.1 O, S
 
 
Animals were treated for 3 months following 12 months of OVX (Figure 2); n=10 in all groups; data are mean ± SEM 
Femur diaphysis was subjected to three point bending to failure. Parameters analyzed include: maximum load (Fu), stiffness (S), energy absorbed 
(W) and toughness (T). Significant differences are indicated with respect to OVX control (O) and Sham (S) control rats (P<0.05 by ANOVA 
Dunnett test) 
Indentation test provided data on mechanical properties of trabecular bone. Parameters analyzed include: maximum load (Fu), stiffness (S), energy 
absorbed (W) and ultimate strength (σ). Significant differences are indicated with respect to OVX control (O) and Sham (S) control rats (P<0.05 
by ANOVA Dunnett test) 
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Figure 2.  
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